Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne F. Peery is active.

Publication


Featured researches published by Anne F. Peery.


Gastroenterology | 2012

Burden of Gastrointestinal Disease in the United States: 2012 Update

Anne F. Peery; Evan S. Dellon; Jennifer L. Lund; Seth D. Crockett; Christopher E. McGowan; William J. Bulsiewicz; Lisa M. Gangarosa; Michelle T. Thiny; Karyn Stizenberg; Douglas R. Morgan; Yehuda Ringel; Hannah P. Kim; Marco DiBonaventura; Charlotte F. Carroll; Jeffery K. Allen; Suzanne F. Cook; Robert S. Sandler; Michael D. Kappelman; Nicholas J. Shaheen

BACKGROUND & AIMS Gastrointestinal (GI) diseases account for substantial morbidity, mortality, and cost. Statistical analyses of the most recent data are necessary to guide GI research, education, and clinical practice. We estimate the burden of GI disease in the United States. METHODS We collected information on the epidemiology of GI diseases (including cancers) and symptoms, along with data on resource utilization, quality of life, impairments to work and activity, morbidity, and mortality. These data were obtained from the National Ambulatory Medical Care Survey; National Health and Wellness Survey; Nationwide Inpatient Sample; Surveillance, Epidemiology, and End Results Program; National Vital Statistics System; Thompson Reuters MarketScan; Medicare; Medicaid; and the Clinical Outcomes Research Initiatives National Endoscopic Database. We estimated endoscopic use and costs and examined trends in endoscopic procedure. RESULTS Abdominal pain was the most common GI symptom that prompted a clinic visit (15.9 million visits). Gastroesophageal reflux was the most common GI diagnosis (8.9 million visits). Hospitalizations and mortality from Clostridium difficile infection have doubled in the last 10 years. Acute pancreatitis was the most common reason for hospitalization (274,119 discharges). Colorectal cancer accounted for more than half of all GI cancers and was the leading cause of GI-related mortality (52,394 deaths). There were 6.9 million upper, 11.5 million lower, and 228,000 biliary endoscopies performed in 2009. The total cost for outpatient GI endoscopy examinations was


Gastroenterology | 2011

Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia

Nicholas J. Shaheen; Bergein F. Overholt; Richard E. Sampliner; Herbert C. Wolfsen; Kenneth K. Wang; David E. Fleischer; Virender K. Sharma; Glenn M. Eisen; M. Brian Fennerty; John G. Hunter; Mary P. Bronner; John R. Goldblum; Ana E. Bennett; Hiroshi Mashimo; Richard I. Rothstein; Stuart R. Gordon; Steven A. Edmundowicz; Ryan D. Madanick; Anne F. Peery; V. Raman Muthusamy; Kenneth J. Chang; Michael B. Kimmey; Stuart J. Spechler; Ali Siddiqui; Rhonda F. Souza; Anthony Infantolino; John A. Dumot; Gary W. Falk; Joseph A. Galanko; Blair A. Jobe

32.4 billion. CONCLUSIONS GI diseases are a source of substantial morbidity, mortality, and cost in the United States.


Gastroenterology | 2015

Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States

Anne F. Peery; Seth D. Crockett; Alfred S. Barritt; Evan S. Dellon; Swathi Eluri; Lisa M. Gangarosa; Elizabeth T. Jensen; Jennifer L. Lund; Sarina Pasricha; Thomas Runge; Monica Schmidt; Nicholas J. Shaheen; Robert S. Sandler

BACKGROUND & AIMS Radiofrequency ablation (RFA) can eradicate dysplasia and intestinal metaplasia in patients with dysplastic Barretts esophagus (BE), and reduce rates of esophageal adenocarcinoma. We assessed long-term rates of eradication, durability of neosquamous epithelium, disease progression, and safety of RFA in patients with dysplastic BE. METHODS We performed a randomized trial of 127 subjects with dysplastic BE; after cross-over subjects were included, 119 received RFA. Subjects were followed for a mean time of 3.05 years; the study was extended to 5 years for patients with eradication of intestinal metaplasia at 2 years. Outcomes included eradication of dysplasia or intestinal metaplasia after 2 and 3 years, durability of response, disease progression, and adverse events. RESULTS After 2 years, 101 of 106 patients had complete eradication of all dysplasia (95%) and 99 of 106 had eradication of intestinal metaplasia (93%). After 2 years, among subjects with initial low-grade dysplasia, all dysplasia was eradicated in 51 of 52 (98%) and intestinal metaplasia was eradicated in 51 of 52 (98%); among subjects with initial high-grade dysplasia, all dysplasia was eradicated in 50 of 54 (93%) and intestinal metaplasia was eradicated in 48 of 54 (89%). After 3 years, dysplasia was eradicated in 55 of 56 of subjects (98%) and intestinal metaplasia was eradicated in 51 of 56 (91%). Kaplan-Meier analysis showed that dysplasia remained eradicated in >85% of patients and intestinal metaplasia in >75%, without maintenance RFA. Serious adverse events occurred in 4 of 119 subjects (3.4%); the rate of stricture was 7.6%. The rate of esophageal adenocarcinoma was 1 per 181 patient-years (0.55%/patient-years); there was no cancer-related morbidity or mortality. The annual rate of any neoplastic progression was 1 per 73 patient-years (1.37%/patient-years). CONCLUSIONS In subjects with dysplastic BE, RFA therapy has an acceptable safety profile, is durable, and is associated with a low rate of disease progression, for up to 3 years.


Gastrointestinal Endoscopy | 2009

Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia.

Nicholas J. Shaheen; Bruce D. Greenwald; Anne F. Peery; John A. Dumot; Norman S. Nishioka; Herbert C. Wolfsen; J.Steven Burdick; Julian A. Abrams; Kenneth K. Wang; Damien Mallat; Mark H. Johnston; Alvin M. Zfass; Jenny O. Smith; James S. Barthel; Charles J. Lightdale

BACKGROUND & AIMS Gastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidity, mortality, and cost in the United States. Quantification and statistical analyses of the burden of these diseases are important for researchers, clinicians, policy makers, and public health professionals. We gathered data from national databases to estimate the burden and cost of GI and liver disease in the United States. METHODS We collected statistics on health care utilization in the ambulatory and inpatient setting along with data on cancers and mortality from 2007 through 2012. We included trends in utilization and charges. The most recent data were obtained from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. RESULTS There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses of hemorrhoids in the ambulatory setting in a year. Functional and motility disorders resulted in nearly 1 million emergency department visits in 2012; most of these visits were for constipation. GI hemorrhage was the most common diagnosis leading to hospitalization, with >500,000 discharges in 2012, at a cost of nearly


Gastroenterology | 2012

A High-Fiber Diet Does Not Protect Against Asymptomatic Diverticulosis

Anne F. Peery; Patrick R. Barrett; Doyun Park; Albert J. Rogers; Joseph A. Galanko; Christopher F. Martin; Robert S. Sandler

5 billion dollars. Hospitalizations and associated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disease have increased during the last 20 years. In 2011, there were >1 million people in the United States living with colorectal cancer. The leading GI cause of death was colorectal cancer, followed by pancreatic and hepatobiliary neoplasms. CONCLUSIONS GI, liver and pancreatic diseases are a source of substantial burden and cost in the United States.


Gastroenterology | 2011

Inverse Association of Esophageal Eosinophilia With Helicobacter pylori Based on Analysis of a US Pathology Database

Evan S. Dellon; Anne F. Peery; Nicholas J. Shaheen; Douglas R. Morgan; Jennifer M. Hurrell; Richard H. Lash; Robert M. Genta

BACKGROUND Endoscopic ablation to treat Barretts esophagus (BE) with high-grade dysplasia (HGD) is associated with a decreased incidence of esophageal adenocarcinoma. Endoscopic spray cryotherapy (CRYO) demonstrates promising preliminary data. OBJECTIVE To assess the safety and efficacy of CRYO in BE with HGD. DESIGN Multicenter, retrospective cohort study. SETTING Nine academic and community centers; treatment period, 2007 to 2009. PATIENTS Subjects with HGD confirmed by 2 pathologists. Previous EMR was allowed if residual HGD remained. INTERVENTIONS CRYO with follow-up biopsies. MAIN OUTCOME MEASUREMENTS Complete eradication of HGD with persistent low-grade dysplasia, complete eradication of all dysplasia with persistent nondysplastic intestinal metaplasia, and complete eradication of all intestinal metaplasia. RESULTS Ninety-eight subjects (mean age 65.4 years, 83% male) with BE and HGD (mean length 5.3 cm) underwent 333 treatments (mean 3.4 treatments per subject). There were no esophageal perforations. Strictures developed in 3 subjects. Two subjects reported severe chest pain managed with oral narcotics. One subject was hospitalized for bright red blood per rectum. Sixty subjects had completed all planned CRYO treatments and were included in the efficacy analysis. Fifty-eight subjects (97%) had complete eradication of HGD, 52 (87%) had complete eradication of all dysplasia with persistent nondysplastic intestinal metaplasia, and 34 (57%) had complete eradication of all intestinal metaplasia. Subsquamous BE was found in 2 subjects (3%). LIMITATIONS Nonrandomized, retrospective study with no control group, short follow-up (10.5 months), lack of centralized pathology, and use of surrogate outcome for decreased cancer risk. CONCLUSIONS CRYO is a safe and well-tolerated therapy for BE and HGD. Short-term results suggest that CRYO is highly effective in eradicating HGD.


Clinical Gastroenterology and Hepatology | 2013

Constipation and a Low-Fiber Diet Are Not Associated With Diverticulosis

Anne F. Peery; Robert S. Sandler; Dennis J. Ahnen; Joseph A. Galanko; Adrian N. Holm; Aasma Shaukat; Leila A. Mott; Elizabeth L. Barry; David A. Fried; John A. Baron

BACKGROUND & AIMS The complications of diverticulosis cause considerable morbidity in the United States; health care expenditures for this disorder are estimated to be


Gastrointestinal Endoscopy | 2012

Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video)

Anne F. Peery; Toshitaka Hoppo; Katherine S. Garman; Evan S. Dellon; Norma Daugherty; Susan Bream; Alejandro F. Sanz; Jon M. Davison; Melissa Spacek; Diane Connors; Ashley L. Faulx; Amitabh Chak; James D. Luketich; Nicholas J. Shaheen; Blair A. Jobe

2.5 billion per year. Many physicians and patients believe that a high-fiber diet and frequent bowel movements prevent the development of diverticulosis. Evidence for these associations is poor. We sought to determine whether low-fiber or high-fat diets, diets that include large quantities of red meat, constipation, or physical inactivity increase risk for asymptomatic diverticulosis. METHODS We performed a cross-sectional study of 2104 participants, 30-80 years old, who underwent outpatient colonoscopy from 1998 to 2010. Diet and physical activity were assessed in interviews using validated instruments. RESULTS The prevalence of diverticulosis increased with age, as expected. High intake of fiber did not reduce the prevalence of diverticulosis. Instead, the quartile with the highest fiber intake had a greater prevalence of diverticulosis than the lowest (prevalence ratio = 1.30; 95% confidence interval, 1.13-1.50). Risk increased when calculated based on intake of total fiber, fiber from grains, soluble fiber, and insoluble fiber. Constipation was not a risk factor. Compared to individuals with <7 bowel movements per week, individuals with >15 bowel movements per week had a 70% greater risk for diverticulosis (prevalence ratio = 1.70; 95% confidence interval, 1.24-2.34). Neither physical inactivity nor intake of fat or red meat was associated with diverticulosis. CONCLUSIONS A high-fiber diet and increased frequency of bowel movements are associated with greater, rather than lower, prevalence of diverticulosis. Hypotheses regarding risk factors for asymptomatic diverticulosis should be reconsidered.


Clinical Gastroenterology and Hepatology | 2011

Variable Reliability of Endoscopic Findings With White-Light and Narrow-Band Imaging for Patients With Suspected Eosinophilic Esophagitis

Anne F. Peery; Hongyuan Cao; Rosalie Dominik; Nicholas J. Shaheen; Evan S. Dellon

BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is of increasing prevalence and believed to result from allergic processes. Helicobacter pylori has been inversely associated with allergic diseases, but there is no known relationship between H pylori, EoE, and esophageal eosinophilia. We investigated the association between esophageal eosinophilia and H pylori infection. METHODS We performed a cross-sectional study of data, collected from a US pathology database, on 165,017 patients in the United States who underwent esophageal and gastric biopsies from 2008 through 2010. Patients with and without H pylori on gastric biopsy were compared, and odds of esophageal eosinophilia were determined. RESULTS From the data analyzed, 56,301 (34.1%) had normal esophageal biopsy specimens, 5767 (3.5%) had esophageal eosinophilia, and 11,170 (6.8%) had H pylori infection. Esophageal eosinophilia was inversely associated with H pylori (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.69-0.87). Compared with patients with normal esophageal biopsy specimens, odds of H pylori were reduced among patients with ≥ 15 eosinophils per high-power field (eos/hpf) (OR, 0.79; 95% CI, 0.70-0.88), ≥ 45 eos/hpf (OR, 0.75; 95% CI, 0.61-0.93), ≥ 75 eos/hpf (OR, 0.72; 95% CI, 0.50-1.03), and ≥ 90 eos/hpf (OR, 0.52; 95% CI, 0.31-0.87) (P for trend <.001). A similar dose-response trend was observed for increasing clinical suspicion for EoE and decreasing prevalence of H pylori. Additionally, severity of histologic effects of H pylori was inversely associated with esophageal eosinophilia. All trends held in multivariate analysis. CONCLUSIONS In a large cross-sectional analysis, H pylori infection was inversely associated with esophageal eosinophilia. This relationship could have implications for the pathogenesis and epidemiology of EoE.


Gastrointestinal Endoscopy | 2010

Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus

Nicholas J. Shaheen; Anne F. Peery; Bergein F. Overholt; Charles J. Lightdale; Amitabh Chak; Kenneth K. Wang; Robert H. Hawes; David E. Fleischer; John R. Goldblum

BACKGROUND & AIMS Asymptomatic diverticulosis is commonly attributed to constipation caused by a low-fiber diet, although evidence for this mechanism is limited. We examined the associations between constipation and low dietary fiber intake with risk of asymptomatic diverticulosis. METHODS We performed a cross-sectional study that analyzed data from 539 individuals with diverticulosis and 1569 without (controls). Participants underwent colonoscopy and assessment of diet, physical activity, and bowel habits. Our analysis was limited to participants with no knowledge of their diverticular disease to reduce the risk of biased responses. RESULTS Constipation was not associated with an increased risk of diverticulosis. Participants with less frequent bowel movements (<7/wk) had reduced odds of diverticulosis compared with those with regular bowel movements (7/wk) (odds ratio [OR], 0.56; 95% confidence interval [CI], 0.40-0.80). Those reporting hard stools also had reduced odds (OR, 0.75; 95% CI, 0.55-1.02). There was no association between diverticulosis and straining (OR, 0.85; 95% CI, 0.59-1.22) or incomplete bowel movement (OR, 0.85; 95% CI, 0.61-1.20). We found no association between dietary fiber intake and diverticulosis (OR, 0.96; 95% CI, 0.71-1.30) in comparing the highest quartile with the lowest (mean intake, 25 vs 8 g/day). CONCLUSIONS In our cross-sectional, colonoscopy-based study, neither constipation nor a low-fiber diet was associated with an increased risk of diverticulosis.

Collaboration


Dive into the Anne F. Peery's collaboration.

Top Co-Authors

Avatar

Nicholas J. Shaheen

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Joseph A. Galanko

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Robert S. Sandler

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Evan S. Dellon

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Mark J. Koruda

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Katherine S. Cools

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amitabh Chak

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Blair A. Jobe

Allegheny Health Network

View shared research outputs
Top Co-Authors

Avatar

Christopher F. Martin

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge